SCHEMBL4243563

SCHEMBL4243563

Cc1cc(C(=O)NN)ccc1NC(=O)c1ccccc1F

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KLK1 P06870 1/20 0.51
KLK5 Q9Y337 1/20 0.51
CNR2 P34972 1/20 0.48
KMT2A Q03164 4/20 0.48
MEN1 O00255 2/20 0.48
TDP1 Q9NUW8 1/20 0.48
L3MBTL1 Q9Y468 3/20 0.47
GAA P10253 1/20 0.47
ALDH1A1 P00352 4/20 0.47
KCNMA1 Q12791 1/20 0.47
MAPT P10636 4/20 0.47
CYP1A2 P05177 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
SMN1; SMN2 Q16637 5/20 0.47
KDM4E B2RXH2 3/20 0.47
POLB P06746 1/20 0.47
KCNH2 Q12809 1/20 0.46
HRH3 Q9Y5N1 1/20 0.46
PKM P14618 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4244885 0.88 KLK1 (0.54) KLK1KLK5KMT2AMEN1TDP1
SCHEMBL4238253 0.86 L3MBTL1 (0.49) CNR2KMT2AMEN1TDP1L3MBTL1
SCHEMBL4250927 0.84 ALDH1A1 (0.64) KLK1KLK5KMT2AMEN1TDP1
SCHEMBL6814841 0.82 MAPT (0.65) CNR2KMT2AMEN1TDP1L3MBTL1
SCHEMBL18083709 0.80 CNR2 (0.49) CNR2KMT2AMEN1TDP1L3MBTL1
SCHEMBL7983000 0.80 KMT2A (0.51) CNR2KMT2AMEN1TDP1L3MBTL1
SCHEMBL4242557 0.77 MEN1 (0.75) KMT2AMEN1TDP1L3MBTL1ALDH1A1
SCHEMBL30608029 0.77 MAPT (0.56) CNR2KMT2AMEN1TDP1L3MBTL1
SCHEMBL4239439 0.77 MEN1 (0.60) KMT2AMEN1TDP1ALDH1A1MAPT
SCHEMBL31425031 0.76 TRPV1 (0.56) CNR2KMT2AMEN1TDP1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090105217-A1 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS GLAXO GROUP LIMITED (GB) 2009-04-23 US disclosed
US-20090105217-A1 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS GLAXO GROUP LIMITED (GB) 2009-04-23 US disclosed
US-20090105217-A1 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS GLAXO GROUP LIMITED (GB) 2009-04-23 US disclosed
WO-2007138033-A1 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS GLAXO GROUP LIMITED (GB) 2007-12-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105217-A1 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS CHRNA7, CHRNA5, CHRNA2 KLK1 3983/4885KLK5 2817/4885CNR2 125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.